Compass Therapeutics (CMPX) EBIT (2018 - 2026)
Compass Therapeutics (CMPX) posted EBIT of -$20.3 million for Q1 2026, down 12.83% sequentially from -$18.0 million in Q4 2025, and down 12.99% YoY from -$23.3 million in Q1 2025.
Compass Therapeutics (CMPX) EBIT (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported EBIT for 9 years, with the latest figure at -$20.3 million in Q1 2026.
- Quarterly EBIT fell 12.99% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$75.2 million (down 21.59% YoY) and the FY2025 annual result came in at -$72.8 million, down 28.63% from the prior year.
- EBIT fell to -$20.3 million in Q1 2026 per CMPX's latest filing, from -$18.0 million in the prior quarter.
- Over five years, EBIT peaked at -$7.2 million in Q1 2022 and troughed at -$21.1 million in Q2 2025.
- A 5-year average of -$14.2 million and a median of -$13.3 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT tumbled 115.2% in 2022, then grew 5.33% in 2023.
- Over 5 years, EBIT stood at -$12.9 million in 2022, then slipped by 19.44% to -$15.4 million in 2023, then retreated by 7.67% to -$16.6 million in 2024, then retreated by 8.54% to -$18.0 million in 2025, then retreated by 12.83% to -$20.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$20.3 million, -$18.0 million, and -$15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | -26.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.98 Mn |
| Mar 31, 2026 | -20.30 Mn |
| Dec 31, 2025 | -17.99 Mn |
| Sep 30, 2025 | -15.82 Mn |
| Jun 30, 2025 | -21.07 Mn |
| Mar 31, 2025 | -17.97 Mn |
| Dec 31, 2024 | -16.57 Mn |
| Sep 30, 2024 | -12.24 Mn |
| Jun 30, 2024 | -15.05 Mn |
| Mar 31, 2024 | -12.77 Mn |
| Dec 31, 2023 | -15.39 Mn |
| Sep 30, 2023 | -11.93 Mn |
| Jun 30, 2023 | -13.34 Mn |
| Mar 31, 2023 | -9.71 Mn |
| Dec 31, 2022 | -12.89 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -8.99 Mn |
| Mar 31, 2022 | -7.18 Mn |
| Dec 31, 2021 | -13.00 Mn |
| Sep 30, 2021 | -5.85 Mn |